Metabolic Liver Complications in Diabetes Mellitus

Metabolic liver complications are increasingly recognised as a central element in the spectrum of diabetes-related organ dysfunction. In both type 1 and type 2 diabetes, chronic hyperglycaemia, insulin resistance and dyslipidaemia promote hepatic fat accumulation (steatosis), progression to inflammatory injury (steatohepatitis) and deposition of fibrous tissue. In type 1 diabetes, fluctuations in exogenous insulin delivery and portal insulin deficiency can precipitate glycogen overload, whereas in type 2 diabetes the clustering of obesity, metabolic syndrome and low-grade inflammation underpins the emergence of non-alcoholic fatty liver disease (NAFLD) and its more aggressive form, non-alcoholic steatohepatitis (NASH). Left unchecked, these processes may culminate in cirrhosis, hepatocellular carcinoma and heightened cardiovascular morbidity. Non-invasive biomarkers and advanced imaging methods now facilitate earlier detection, while lifestyle modification, optimised glycaemic control and targeted pharmacotherapies are under active investigation to arrest or reverse disease progression.

Research from Nature Portfolio

A cross-sectional study of individuals with type 1 diabetes has demonstrated that fatty liver changes are independently associated with increased carotid intima-media thickness, a surrogate of subclinical atherosclerosis. The relationship persisted after adjustment for conventional cardiovascular risk factors, underscoring the liver’s role as a modulator of systemic vascular health in diabetes mellitus and highlighting the need to integrate hepatic assessment into cardiovascular risk stratification.

Metabolic Liver Complications in Diabetes Mellitus publication trend

The graph below shows the total number of articles in metabolic liver complications in diabetes mellitus across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic dysfunction–associated steatotic liver disease (MASLD): A spectrum of liver pathology beginning with steatosis in the context of metabolic risk factors.

Non-alcoholic steatohepatitis (NASH): Inflammatory and fibrotic progression of fatty liver disease in the absence of significant alcohol intake.

Glycogenic hepatopathy: Excessive glycogen accumulation in hepatocytes, often reversible with improved glycaemic control.

Steatosis: Accumulation of triglycerides within liver cells, manifesting as fatty change.

Fibrosis: Deposition of extracellular matrix proteins in liver tissue, marking progression towards scarring.

Transient elastography: A non-invasive imaging technique that measures liver stiffness as a surrogate for fibrosis severity.

References

1. Nonalcoholic Fatty Liver Disease is Associated with Increased Carotid Intima-Media Thickness in Type 1 Diabetic Patients. Scientific Reports (2016).
2. Machine Learning Identifies Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism (2024).
3. Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes. European Journal of Endocrinology (2024).
4. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Diabetes & Metabolism (2023).